Brief: Grifols Gets Regulatory Approval For Fibrinogen Concentrate In Germany
13/11/2025 09:07
Nov 13 (Reuters) - Grifols SA GRLS.MC: ITS BIOTEST RECEIVES FIRST REGULATORY APPROVAL FOR ITS FIBRINOGEN CONCENTRATE GERMANY IS FIRST COUNTRY TO GRANT MARKETING AUTHORIZATION, TO BE FOLLOWED BY OTHER EUROPEAN COUNTRIES SUCH AS AUSTRIA AND SPAIN NEW THERAPY APPROVED FOR BOTH CONGENITAL AND ACQUIRED FIBRINOGEN DEFICIENCY NEW THERAPY EXPECTED TO BE AVAILABLE TO PATIENTS IN GERMANY BY END OF 2025 REGULATORY PROCEDURE IN AUSTRIA AND SPAIN EXPECTED TO FOLLOW IN 2026 Source text Further company coverage: GRLS.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 567 69 66 00;))
Recent news on Grifols SA
See all newsSpanish stocks - Factors to watch on June 24
Brief: Grifols Approves Reduction Of Up To 10% Of Its Share Capital
Brief: Grifols Launches Fibrinogen Concentrate For Acute Bleeding Episodes In The U.S.
Brief: Grifols' Egypt Unit Adds €180 Mln Of Additional Investment In Project
Spanish stocks - Factors to watch on June 12